CHMP recommends approval of Zykadia for ALK+ advanced NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of expanding the use of Zykadia (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login